Ubs Asset Management Americas Inc Sage Therapeutics, Inc. Transaction History
Ubs Asset Management Americas Inc
- $417 Billion
- Q4 2024
A detailed history of Ubs Asset Management Americas Inc transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 85,566 shares of SAGE stock, worth $615,219. This represents 0.0% of its overall portfolio holdings.
Number of Shares
85,566
Previous 72,149
18.6%
Holding current value
$615,219
Previous $520,000
10.77%
% of portfolio
0.0%
Previous 0.0%
Shares
28 transactions
Others Institutions Holding SAGE
# of Institutions
194Shares Held
45MCall Options Held
304KPut Options Held
117K-
Black Rock Inc. New York, NY5.22MShares$37.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.84MShares$34.8 Million0.0% of portfolio
-
Morgan Stanley New York, NY4.59MShares$33 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V84.46MShares$32.1 Million0.48% of portfolio
-
Rtw Investments, LP New York, NY3MShares$21.6 Million0.27% of portfolio
About Sage Therapeutics, Inc.
- Ticker SAGE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,422,300
- Market Cap $427M
- Description
- Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...